Cargando…

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies

A fixed‐dose subcutaneous (s.c.) formulation of the anti‐CD20 antibody, rituximab, has been developed to address safety, infusion time, and patient comfort concerns relating to intravenous (i.v.) dosing, and has been approved based upon a pharmacokinetic (PK)–clinical bridging strategy, which demons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamois, Candice, Gibiansky, Ekaterina, Gibiansky, Leonid, Chavanne, Clarisse, Morcos, Peter N., McIntyre, Christine, Barrett, Martin, Lundberg, Linda, Zharkov, Artem, Boehnke, Axel, Frey, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597022/ https://www.ncbi.nlm.nih.gov/pubmed/34041738 http://dx.doi.org/10.1002/cpt.2308

Ejemplares similares

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Gibiansky, Ekaterina, et al.
Publicado: (2021)

Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis
por: Jamois, Candice, et al.
Publicado: (2022)

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study
por: Gibiansky, Ekaterina, et al.
Publicado: (2019)

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
por: Gibiansky, E, et al.
Publicado: (2014)

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019)

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
por: Davies, Andrew, et al.
Publicado: (2017)

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Wang, Xiaofeng, et al.
Publicado: (2020)

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
por: Pouzin, Clemence, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
por: Wei, Xiaohui, et al.
Publicado: (2017)

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors
por: Gibiansky, Leonid, et al.
Publicado: (2022)

Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants
por: Gibiansky, Leonid, et al.
Publicado: (2020)

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
por: Brancati, Serena, et al.
Publicado: (2021)

Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders
por: Schieber, Timothy, et al.
Publicado: (2023)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

List of approved SC experiements as of 24.2.69
por: CERN. Geneva. Physics III Committee
Publicado: (1969)

List of approved SC experiments as of 22.2.68
por: CERN. Geneva. Physics III Committee
Publicado: (1968)

List of approved SC experiments as of 8.5.68
por: CERN. Geneva. Physics III Committee
Publicado: (1968)

Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors
por: Passey, Chaitali, et al.
Publicado: (2023)

Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment Failure
por: Jorga, Karin, et al.
Publicado: (2018)

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
por: Salles, Gilles, et al.
Publicado: (2017)

Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon‐γ–Induced Protein 10, BMS‐986184, in Healthy Participants to Guide Therapeutic Dosing
por: Cai, Weiguo, et al.
Publicado: (2020)

List of PH III experiments 71-51: approved experiments at the SC
por: CERN. Geneva. Physics III Committee
Publicado: (1971)

List of PH III experiments, 72.16: approved experiments at the SC
por: CERN. Geneva. Physics III Committee
Publicado: (1972)

List of PH III experiments, 72-31: approved experiments at the SC
por: CERN. Geneva. Physics III Committee
Publicado: (1972)

List of PH III experiments, 72-60: approved experiments at the SC
por: CERN. Geneva. Physics III Committee
Publicado: (1972)

List of PH III experiments 73-3: approved experiments at the SC
por: CERN. Geneva. Physics III Committee
Publicado: (1973)

List of PH III experiments, 71-6: approved experiments at the SC
por: CERN. Geneva. Physics III Committee
Publicado: (1971)

List of PH III experiments, 71-30: approved experiments at the SC
por: CERN. Geneva. Physics III Committee
Publicado: (1971)

List of PH III experiments, 70-44: approved experiments at the SC
por: CERN. Geneva. Physics III Committee
Publicado: (1970)

List of PH III experiments, 70-31: approved experiments at the SC
por: CERN. Geneva. Physics III Committee
Publicado: (1970)

Safety of switching between rituximab biosimilars in onco-hematology
por: Urru, Silvana A. M., et al.
Publicado: (2021)

Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug‐disease modelling for dosing regimen optimization
por: Sturm, Stefan, et al.
Publicado: (2020)

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021)

The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience
por: Nissen, Johanna C, et al.
Publicado: (2014)

Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma
por: Samineni, Divya, et al.
Publicado: (2021)

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers
por: Jamois, Candice, et al.
Publicado: (2009)

FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment
por: Ho, Cheryl, et al.
Publicado: (2022)

Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment
por: Wang, Honglei, et al.
Publicado: (2020)

Editorial: Molecular Bridges Between Hematology and Inflammation
por: Kasirer-Friede, Ana
Publicado: (2019)

Interplay between type IV pili activity and exopolysaccharides secretion controls motility patterns in single cells of Myxococcus xanthus
por: Hu, Wei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kfm08n79nugtme0o7qbec5mp28